Regulatory approval is next: Mizuho lifts Biogen to buy on news of Alzheimer’s drug success
admin Next stop regulatory approval. That was the view of analysts at Mizuho Securities, who late…
Read MoreHealthcare
Eisai shares indicated sharply higher after trial of experimental drug slows Alzheimer’s progression
Eisai Co. shares were indicated sharply higher Wednesday morning after the Japanese drug maker and…
Read MoreAlzheimer’s drug from Eisai, Biogen shows promise in large trial
Eisai Co. 4523, +0.89% and Biogen Inc. BIIB, +1.04% said their experimental Alzheimer’s disease drug…
Read MoreOpinion: Feeding people on this warming Earth requires future-proofing our agri-food systems. Here’s how.
These days, it is easy to feel overwhelmed. A worsening regional conflict in Ukraine, overlain…
Read MoreMelt Pharmaceuticals files for IPO
Melt Pharmaceuticals, Inc. filed for an initial public offering with the Securities and Exchange Commission…
Read MoreFDA warns ‘NyQuil chicken’ is ‘a recipe for danger’
What the actual cluck? The latest seriously questionable social-media trend apparently has people sautéing chicken…
Read MoreJudge denies DOJ’s request to block UnitedHealth’s acquisition of Change Healthcare
WASHINGTON — A federal judge Monday ruled against a Justice Department antitrust challenge to UnitedHealth…
Read MoreRoche’s vision-loss drug Vabysmo gets EU nod
Roche Holding AG said Monday that its vision-loss treatment Vabysmo has been approved in the…
Read MoreMarket rout casts cloud over biggest IPO of the year as at least two deals are pulled during brutal selloff
At least two initial public offerings were withdrawn during Tuesday’s brutal stock market rout, casting…
Read More
Here’s why one strategist says the consumer and related stocks might get a second wind
Welcome to intervention Wednesday. The Bank of England has halted, at least for now, soaring…
Read More